Synapse - Works

Results (115370)

Randomized phase II trial of olaparib + pembrolizumab vs olaparib alone as maintenance therapy in patients with metastatic pancreatic cancer with germline BRCA1 or BRCA2 mutations: SWOG S2001 NCT04548752

Meeting Abstract

Chung, V.; Guthrie, K. A.; Pishvaian, M. J.; Lowy, A. M.; Sohal, D.; Reiss, K. A.; Sanford, N. N.; Allegra, C.; Colby, S.; O'Reilly, E. M.; more...
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

HERIZON-BTC-302: A phase 3 study of zanidatamab with standard-of-care (SOC) therapy vs SOC alone for first-line treatment of human epidermal growth factor receptor 2 (HER2)-positive advanced/metastatic biliary tract cancer (BTC)

Meeting Abstract

Harding, J. J.; Macarulla, T.; Pant, S.; Wu, X.; Garfin, P. M.; Okusaka, T.
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

A phase II study of agenT-797 (invariant natural killer T-cells), botensilimab (Fc-enhanced CTLA-4 inhibitor) and balstilimab (anti-PD-1) in patients with advanced, refractory gastroesophageal adenocarcinoma

Meeting Abstract

Cytryn, S. L.; Maron, S. B.; Janjigian, Y. Y.
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

A phase I trial of intraperitoneal (IP) mesothelin (MSLN)-targeted CAR T-cell therapy in patients with MSLN-positive esophagogastric cancer (EGC) with peritoneal carcinomatosis

Meeting Abstract

Choo, J.; Saini, J.; Gonzalez-Aguirre, A.; Dahi, P.; Hieronymi, S.; Fernstedt, S.; Tan, K. S.; Adusumilli, P. S.; Ku, G. Y.
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

Alliance A022101/NRG-GI009: A pragmatic randomized phase III trial evaluating total ablative therapy for patients with limited metastatic colorectal cancer—Evaluating radiation, ablation, and surgery (ERASur)

Meeting Abstract

Romesser, P. B.; Miller, E. D.; Shi, Q.; Dixon, J. G.; Gholami, S.; White, S. B.; Wu, C.; Goulet, C. C.; Jee, K. W.; Wright, C. L.; more...
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

Phase 1/2 study of FOG-001, a first-in-class direct β-catenin:TCF inhibitor, in patients with colorectal cancer, hepatocellular carcinoma, and other locally advanced or metastatic solid tumors

Meeting Abstract

Papadopoulos, K. P.; Cecchini, M.; Khushman, M. M.; Pelster, M.; Rodon Ahnert, J.; Kummar, S.; Yaeger, R.; Sharma, S.; Wells, A. L.; Garofalo, A.; more...
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

KEYMAKER-U06: Phase 1/2 umbrella platform study of TROP2 antibody-drug conjugate sacituzumab tirumotecan plus pembrolizumab plus chemotherapy (substudy 06C) and sacituzumab tirumotecan plus paclitaxel (substudy 06D) in gastroesophageal adenocarcinoma

Meeting Abstract

Oh, D. Y.; Xu, J.; Tabernero, J.; Van Cutsem, E.; He, T.; Bhaumik, S.; Bhagia, P.; Janjigian, Y. Y.
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

Preclinical and phase 1/2 data of the CHK1 inhibitor BBI-355 in development for esophageal and gastric cancers (EGC) with EGFR or FGFR2 amplifications

Meeting Abstract

Maron, S. B.; Sharma, M. R.; Spira, A. I.; Rodriguez Rivera, I. I.; Chawla, S. P.; Philipovskiy, A.; Johnson, M. L.; Falchook, G. S.; Wainberg, Z. A.; Hansen, R.; more...
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

Valemetostat and trastuzumab deruxtecan (T-DXd) in previously treated advanced or metastatic human epidermal growth factor receptor 2 (HER2)-positive gastric cancer or gastro-esophageal junction (GEJ) adenocarcinoma

Meeting Abstract

Shitara, K.; Enzinger, P. C.; Mohapatra, A.; Janjigian, Y. Y.
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

CLARITY-Gastric 01: A randomized phase 3 study of AZD0901, a Claudin18.2 (CLDN18.2)-targeted antibody-drug conjugate, in second- or later-line (2L+) advanced gastric or gastroesophageal junction cancer (GC/GEJC)

Meeting Abstract

Janjigian, Y. Y.; Shitara, K.; Elimova, E.; Zhang, J.; Chen, M. H.; Smyth, E. C.; Lee, J.; Miao, R.; Liu, S.; Holmblad, M.; more...
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save